---
schema_version: "secwatch.filing_event.v1"
accession: "0001831283-23-000079"
form_type: "8-K"
ticker: "LIANY"
cik: "0001831283"
company_name: "LianBio"
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:44:20.815927+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# LianBio Q1 net loss $24M; mavacamten NDA accepted in China with priority review

## Summary
- Net loss of $24.0M in Q1 2023 vs $27.7M in Q1 2022; cash $286.6M at March 31, 2023.
- Phase 3 EXPLORER-CN trial of mavacamten met primary endpoint in Chinese oHCM patients.
- China NMPA accepted mavacamten NDA with priority review; approved in Macau in May 2023.
- Pascal Qian promoted to Chief Commercial Officer to lead mavacamten launch preparations.
- Cash runway projected through end of 2024; key milestones for TP-03, infigratinib, BBP-398.

## SEC filing metadata
- accession: 0001831283-23-000079
- form_type: 8-K
- ticker: LIANY
- cik: 0001831283
- company_name: LianBio
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831283/000183128323000079/0001831283-23-000079-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831283/000183128323000079/lian-20230511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001831283-23-000079
- JSON: https://secwatch.observer/filing/0001831283-23-000079.json
- Plain text: https://secwatch.observer/filing/0001831283-23-000079.txt

## Key facts
- Earnings Releases
  LianBio reported the first quarter ended March 31, 2023 results: net income $24.0 million.
  - Period: the first quarter ended March 31, 2023
  - Net income: $24.0 million
  - Result: reported results
  source text: Net loss was $24.0 million for the first quarter of 2023 compared to net loss of $27.7 million for the first quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831283/000183128323000079/0001831283-23-000079-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.